Highlights to be presented at Novo Nordisk's Capital

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Highlights to be presented at Novo Nordisk's Capital Markets Day 2015

Bagsværd, Denmark, 18 November 2015 - At Novo Nordisk's Capital Markets Day tomorrow, 19 November 2015, the company will provide updates on key development projects, market dynamics and commercial strategy.

Novo Nordisk's ambition is to further expand its leadership in the global diabetes care market by discovering, developing and marketing improved insulin and GLP-1 analogues, and combinations hereof, as well as completely new classes of anti-diabetic biologics.

The key topics of the day will be:

  • Novo Nordisk's research strategy and key development projects within diabetes care
  • Novo Nordisk's commercial strategy in the global diabetes care market
  • The market dynamics in the United States pharmaceutical market with focus on upcoming product launches

 

 

In addition, the Capital Markets Day will include presentations of the company's production strategy, plans for building a leading position within medical treatment of obesity, as well as break-out sessions covering International Operations, China and the company's biopharmaceuticals business. 

NOVO NORDISK'S RESEARCH STRATEGY AND KEY DEVELOPMENT PROJECTS WITHIN DIABETES CARE

Highlights from this session include: 

Introduction to Novo Nordisk's research strategy and key early development projects

Novo Nordisk's dedicated research and development strategy will be presented with special focus on what Novo Nordisk considers its key competitive advantages throughout the research and development value chain. The presentation will outline the company's research strategy for delivering future innovative protein-based therapies addressing unmet medical needs within the four core disease areas in Novo Nordisk's corporate strategy; Diabetes Care, Obesity, Haemophilia and Growth Disorders. Moreover, it will review Novo Nordisk's development organisation with focus on clinical trial design and execution.  

Results from the SUSTAIN 4 trial comparing once-weekly subcutaneous administration of the GLP-1 analogue semaglutide with once-daily insulin glargine

SUSTAIN 4, the third phase 3a trial for semaglutide to report results, included a total of 1,089 people with type 2 diabetes previously treated with metformin with or without sulfonylurea. From a mean baseline, HbA 1c of 8.2%, people treated once-weekly with doses of 0.5 mg and 1.0 mg semaglutide achieved statistically significant and superior improvements in HbA 1c of 1.2% and 1.6%, respectively, compared to 0.8% with insulin glargine after 30 weeks of treatment. The mean daily insulin glargine dose was 29 units. Furthermore, from a mean baseline body weight of 93 kg, people treated with 0.5 mg and 1.0 mg semaglutide experienced statistically significant and superior weight loss of 3.5 kg and 5.2 kg, respectively, compared with a weight gain of 1.2 kg with insulin glargine. In the trial, semaglutide appeared to have a safe and well-tolerated profile. The most common adverse event was nausea which diminished over time. Nausea was reported by up to 22% of people treated with semaglutide compared with 4% of people treated with insulin glargine. Severe or blood glucose-confirmed symptomatic hypoglycaemia was experienced by 4% and 6% of people treated with 0.5 mg or 1.0 mg once-weekly semaglutide, respectively, compared with 11% in the insulin glargine group. 

Results from the phase 2 programme with oral semaglutide and the design of the phase 3a programme PIONEER

Further details from the phase 2 programme with the once-daily oral GLP-1 analogue, oral semaglutide, will be presented. The design of the pivotal phase 3a programme for oral semaglutide, PIONEER, will be highlighted. A total of 10 studies with more than 9,000 patients will be initiated under the planned phase 3a programme. The first trial will be initiated in the first quarter of 2016 and the majority of the remaining trials will be initiated in 2016. Results from the 10 clinical trials are expected to be available in 2018.  

Novo Nordisk's plans for post-approval phase 3b and phase 4 development trials

In addition to the extensive investments in pivotal phase 3a development programmes, Novo Nordisk plans to expand investments in phase 3b and phase 4 clinical trials, in order to support the recently approved products. More than 20 late-stage diabetes care development trials are currently ongoing or planned for initiation in the coming years.  

Biopharmaceuticals break-out session to highlight results from the N8-GP (NN7088) pathfinder 2 extension trial 

In a separate session, Novo Nordisk will present the company's biopharmaceuticals business including results from the completion of the first part of the pathfinder 2 extension trial. The reported data provide additional support that the long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol), appears to have a safe and well-tolerated profile, and that 95% of mild to moderate bleeds can be managed with 1-2 infusions. Additionally, a subset of 55 patients, who experienced <=2 bleeds during 6 months on every four days prophylaxis, were in the extension phase randomised to either every four days (50 IU/kg) or once-weekly (75 IU/kg) treatment. During the 180-day observation period of this sub-study, the median annualised bleeding rate (ABR) was 0 (zero) for patients in both treatment arms. 

NOVO NORDISK'S COMMERCIAL STRATEGY IN THE GLOBAL DIABETES CARE MARKET

Based on a review of the dynamics of the global diabetes care market, this session will highlight Novo Nordisk's current and expected future growth drivers. These include focusing on the underlying diabetes care market volume growth and Novo Nordisk's introduction of novel drug candidates in the diabetes care market leading to potential market share gains and value upgrade. In the coming years, Novo Nordisk will promote  a complete diabetes care product offering by continuing the global launches of Tresiba ® , Ryzodeg ® and Xultophy ® as well as the planned introduction of faster-acting insulin aspart and semaglutide upon successful completion of the clinical trials and subsequent regulatory processes. 

 

NOVO NORDISK'S COMMERCIAL STRATEGY IN THE UNITED STATES PHARMACEUTICAL MARKET WITH FOCUS ON UPCOMING PRODUCT LAUNCHES

This session includes an update on recent changes in the US healthcare system and payer landscape. The business update will highlight Novo Nordisk's position in the US diabetes care market where the basal insulin segment represents the company's largest opportunity. Tresiba ® is expected to be launched in early 2016, and the launch plans will be outlined during the session. 

 

WEB CAST DETAILS

All sessions of the Capital Markets Day will be webcast live, and replay will be made available on the investor section of novonordisk.com . Presentation material for the Capital Markets Day 2015 will be available 19 November at approximately 8.00 CET, corresponding to 2.00 am EST on the investor section of novonordisk.com .

 

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com , Facebook , Twitter , LinkedIn , YouTube

Further information

Media:    
Mike Rulis +45 3079 3573 mike@novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com
  Investors:    
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Daniel Bohsen +45 3079 6376 dabo@novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com
Kasper Veje +45 3079 8519 kpvj@novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni@novonordisk.com

Company announcement No 72 / 2015

HUG#1967802

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 121

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 28

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 83

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 30

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 106

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 22

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 81

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 111

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched for SelectQuote, Inc. Shareholders

Updated Category News Views 231

Rosen Law Firm Investigates SelectQuote, Inc. Securities Claims The Rosen Law Firm has recently announced an investigation focusing on SelectQuote, Inc. (NYSE: SLQT) due to potential securities claims that may affect shareholders. The firm is dedicated to upholding investor rights and protecting shareholders from misleading information that might influence stock...

Continue Reading
Indonesia's IDX Composite Index Experiences Minor Decline

Updated Category News Views 239

Well, let’s cut to the chase. Indonesia's stock market is feeling a bit queasy lately. The IDX Composite Index slipped by 0.18%, taking a hit thanks to major sectors like Financials, Infrastructure, and Agriculture showing significant losses. This isn’t just some random shuffle; these sectors often serve as economic bellwethers that reflect broader trends in the...

Continue Reading
Trade Tensions Impact Qualcomm Stock Performance Today

Updated Category News Views 126

Trade Tensions Impact Qualcomm Shares Qualcomm Inc (NASDAQ: QCOM) is experiencing a decline in its share price, attributed to rising trade tensions. Reports indicate that the U.S. government is preparing to implement restrictions on AI chip shipments to certain Southeast Asian countries, primarily Malaysia and Thailand, due to ongoing concerns regarding China. New Export...

Continue Reading
Historic $100 Million Donation to Improve Pediatric Mental Health

Updated Category News Views 184

Transforming Pediatric Behavioral Health BOSTON — A groundbreaking gift of $100 million from Rob and Karen Hale has been announced by Boston Children's Hospital. This donation marks the largest in the hospital's storied history and is set to revolutionize pediatric behavioral health care. The Hale family's incredible generosity is aimed at reimagining how mental and...

Continue Reading
Mark Carney Takes Charge: Canada's Bold Steps to Trade Victory

Updated Category News Views 414

Mark Carney: Canada's New Prime Minister Mark Carney has emerged victorious in the leadership race of the Liberal Party, succeeding Justin Trudeau as Canada’s prime minister. With a commanding win, he pledged to confront U.S. President Donald Trump head-on, especially regarding increasing trade tensions. A Strong Start in Leadership In a remarkable demonstration of...

Continue Reading